Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Personalis Inc PSNL

Technology Scientific & Technical Instruments
Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome... see more

Recent & Breaking News (NDAQ:PSNL)

Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay

Business Wire March 7, 2023

Personalis Appoints Christopher Hall as Chief Executive Officer

Business Wire March 2, 2023

Personalis Reports Fourth Quarter and Full Year 2022 Financial Results

Business Wire February 23, 2023

Personalis to Announce Fourth Quarter and Full Year 2022 Financial Results

Business Wire February 9, 2023

Personalis to Participate at Upcoming Investor Conferences

Business Wire February 6, 2023

Personalis and Moderna Sign New Agreement to Leverage NeXT Platform(TM) in Personalized mRNA Cancer Vaccine Clinical Trials

Business Wire February 3, 2023

Personalis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue

Business Wire January 4, 2023

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire December 16, 2022

Personalis Announces CEO Retirement and Transition

Business Wire December 14, 2022

Personalis and UCSF to Study Clinical Utility of ctDNA for Treatment Response in Colorectal Cancer

Business Wire November 30, 2022

Personalis to Present at the 34th Annual Piper Sandler Healthcare Conference

Business Wire November 21, 2022

Personalis Presents Data from New Platform Features at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Business Wire November 7, 2022

Personalis Reports Third Quarter 2022 Financial Results

Business Wire November 2, 2022

Personalis Grows Leadership Team with Appointment of Christopher Hall as Senior Vice President and Head, Diagnostics Business

Business Wire October 31, 2022

Personalis to Announce Third Quarter 2022 Financial Results

Business Wire October 19, 2022

Personalis Forms Research Collaboration to Better Predict Immunotherapy Response for Gastroesophageal Cancer

Business Wire October 4, 2022

Personalis to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

Business Wire August 30, 2022

Personalis Adds New MRD Patent Covering the Combination of Tumor-Informed and Database-Derived Content to Patent Infringement Complaint Against Foresight Diagnostics

Business Wire August 17, 2022

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire August 16, 2022

Personalis to Participate at the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference

Business Wire August 4, 2022